News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
228,310 Results
Type
Article (7230)
Company Profile (16)
Press Release (221064)
Multimedia
Podcasts (3)
Webinars (1)
Section
Business (63193)
Career Advice (294)
Deals (14786)
Drug Delivery (28)
Drug Development (36844)
Employer Resources (24)
FDA (6431)
Job Trends (4911)
News (121962)
Policy (11649)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (1)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (1)
2024 Lone Star Bio Digital (1)
Academia (574)
Accelerated approval (2)
Adcomms (7)
Allergies (35)
Alliances (14779)
ALS (28)
Alzheimer's disease (600)
Antibody-drug conjugate (ADC) (40)
Approvals (6477)
Artificial intelligence (102)
Autoimmune disease (10)
Automation (3)
Bankruptcy (147)
Best Places to Work (4609)
BIOSECURE Act (2)
Biosimilars (20)
Biotechnology (18)
Bladder cancer (48)
Brain cancer (14)
Breast cancer (105)
Cancer (1119)
Cardiovascular disease (70)
Career advice (258)
Career pathing (4)
CAR-T (89)
Cell therapy (215)
Cervical cancer (12)
Clinical research (31210)
Collaboration (301)
Compensation (89)
Complete response letters (7)
COVID-19 (722)
CRISPR (18)
C-suite (74)
Cystic fibrosis (37)
Data (1275)
Denatured (1)
Depression (19)
Diabetes (108)
Diagnostics (2228)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (48)
Drug pricing (41)
Drug shortages (17)
Duchenne muscular dystrophy (39)
Earnings (33302)
Editorial (13)
Employer branding (1)
Employer resources (19)
Events (31027)
Executive appointments (246)
FDA (7093)
Featured Employer (3)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (265)
Gene editing (46)
Generative AI (10)
Gene therapy (128)
GLP-1 (184)
Government (1258)
Grass and pollen (2)
Guidances (34)
Healthcare (6150)
Huntington's disease (5)
IgA nephropathy (14)
Immunology and inflammation (36)
Indications (17)
Infectious disease (783)
Inflammatory bowel disease (58)
Inflation Reduction Act (5)
Influenza (23)
Intellectual property (51)
Interviews (45)
IPO (8043)
IRA (17)
Job creations (572)
Job search strategy (221)
Kidney cancer (8)
Labor market (5)
Layoffs (40)
Leadership (3)
Legal (2105)
Liver cancer (38)
Lung cancer (159)
Lymphoma (80)
Machine learning (1)
Management (7)
Manufacturing (103)
MASH (36)
Medical device (4591)
Medtech (4592)
Mergers & acquisitions (7094)
Metabolic disorders (277)
Multiple sclerosis (38)
NASH (8)
Neurodegenerative disease (25)
Neuropsychiatric disorders (4)
Neuroscience (804)
NextGen: Class of 2025 (1505)
Non-profit (713)
Northern California (1256)
Obesity (138)
Opinion (75)
Ovarian cancer (53)
Pain (35)
Pancreatic cancer (45)
Parkinson's disease (66)
Partnered (5)
Patents (133)
Patient recruitment (60)
Peanut (17)
People (14547)
Pharmaceutical (8)
Pharmacy benefit managers (6)
Phase I (9957)
Phase II (13733)
Phase III (10301)
Pipeline (719)
Policy (32)
Postmarket research (796)
Preclinical (3633)
Press Release (9)
Prostate cancer (50)
Psychedelics (11)
Radiopharmaceuticals (118)
Rare diseases (156)
Real estate (1007)
Recruiting (7)
Regulatory (9154)
Reports (13)
Research institute (511)
Resumes & cover letters (39)
Rett syndrome (3)
RNA editing (2)
RSV (16)
Schizophrenia (26)
Series A (43)
Series B (30)
Service/supplier (2)
Sickle cell disease (23)
Southern California (1095)
Special edition (2)
Spinal muscular atrophy (31)
Sponsored (14)
Startups (680)
Stomach cancer (5)
Supply chain (25)
Tariffs (2)
The Weekly (1)
United States (10492)
Vaccines (166)
Venture capitalists (5)
Weight loss (76)
Women's health (6)
Worklife (4)
Date
Today (80)
Last 7 days (242)
Last 30 days (1192)
Last 365 days (15863)
2025 (4525)
2024 (16931)
2023 (19106)
2022 (22310)
2021 (23684)
2020 (21848)
2019 (14472)
2018 (10673)
2017 (11482)
2016 (9566)
2015 (11762)
2014 (8122)
2013 (5906)
2012 (6060)
2011 (6765)
2010 (6233)
Location
Africa (176)
Alabama (16)
Alaska (2)
Arizona (54)
Arkansas (3)
Asia (17566)
Australia (4862)
California (2839)
Canada (1111)
China (237)
Colorado (120)
Connecticut (161)
Delaware (58)
Europe (28029)
Florida (419)
Georgia (68)
Idaho (6)
Illinois (205)
India (20)
Indiana (123)
Japan (89)
Kansas (14)
Kentucky (5)
Louisiana (5)
Maine (36)
Maryland (350)
Massachusetts (2027)
Michigan (51)
Minnesota (102)
Missouri (35)
Montana (11)
Nebraska (8)
Nevada (39)
New Hampshire (36)
New Jersey (978)
New Mexico (3)
New York (906)
North Carolina (390)
North Dakota (2)
Northern California (1256)
Ohio (62)
Oklahoma (1)
Oregon (7)
Pennsylvania (665)
Puerto Rico (6)
Rhode Island (8)
South America (302)
South Carolina (10)
Southern California (1095)
Tennessee (42)
Texas (425)
Utah (65)
Virginia (76)
Washington D.C. (17)
Washington State (345)
West Virginia (2)
Wisconsin (11)
228,310 Results for "cochlear limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cochlear North America Celebrates International Cochlear Implant Day by Announcing 2025 Academic Scholarship Winners
February 26, 2025
·
5 min read
Press Releases
First Two Participants Successfully Enrolled In Pivotal Clinical Study For Breakthrough Fully Implanted Cochlear Implant
February 24, 2025
·
7 min read
Cochlear receives FDA clearance to lower the age for the Osia System to 5-years-old
Cochlear Limited (ASX: COH) obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™ Osia System from 12 years-old to 5-years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).
April 19, 2024
·
4 min read
Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies
Sensorion announces that promising new data and analysis results from the SENS-401 following cochlear implantation Phase 2a clinical study will be presented at the 17th International Conference on Cochlear Implants and Other Implantable Technologies taking place on July 10-13, 2024, in Vancouver, Canada.
June 20, 2024
·
5 min read
BioForest
Sound Pharmaceuticals’ IND Involving Cochlear Implantation Allowed by the FDA
Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI).
May 20, 2024
·
3 min read
Press Releases
Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear Implant
March 31, 2025
·
15 min read
Drug Development
Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
Sensorion announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.
February 1, 2024
·
5 min read
Cochlear™ Osia® System becomes industry’s first active bone conduction system to enable MRI at 3 Tesla
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).
August 18, 2023
·
5 min read
FDA
FDA approves Cochlear’s Nucleus 8 Sound Processor, smaller, smarter, better connected cochlear implant technology
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, receives U.S. Food and Drug Administration (FDA) approval for the Cochlear™ Nucleus® 8 Sound Processor.
November 1, 2022
·
7 min read
BioMidwest
New Clinical Publication Reports First Three Patients in Early Feasibility Trial for Envoy Medical’s Fully Implanted Cochlear Device
A recent clinical publication in the Journal of Clinical Medicine (JCM) highlighted early surgical experience with Envoy Medical®, Inc.’s (“Envoy Medical”) (NASDAQ: “COCH”) investigational Acclaim® fully implantable cochlear implant.
October 19, 2023
·
8 min read
1 of 22,831
Next
